Related Experiment Video
Updated: Mar 10, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management
Prithviraj Bose1, Srdan Verstovsek1
1From The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
The unprecedented success of ruxolitinib in myelofibrosis (MF) has paved the way for the development of other Janus kinase (JAK) inhibitors and other agents representing diverse drug classes and mechanisms of action in myeloproliferative neoplasms (MPNs). In particular, the symptomatic benefits afforded by ruxolitinib have led to the recognition of "clinical improvement" in symptoms and the spleen in international consensus response criteria for MF. Ruxolitinib is also approved for the second-line treatment of polycythemia vera and is being developed for essential thrombocythemia. Appreciation of the universal role of activated JAK/signal transducer and activator of transcription (STAT) signaling in MPNs and improved understanding of the canonical and noncanonical actions of JAK2 have yielded a number of drug targets beyond JAK2 in MPNs, which form the basis for a number of ruxolitinib-based rational combinations that are being explored in MF. Other JAK inhibitors with the potential for significantly less myelosuppression or even improvement of anemia continue to be tested. Finally, agents with very distinct mechanisms of action, such as novel interferon formulations, antifibrotic agents, and telomerase inhibitors, are being pursued in polycythemia vera and MF, respectively. This article reviews the current landscape of clinical drug development in MPNs, focusing on the most promising agents and combinations.
Insights
Ruxolitinib has advanced myelofibrosis (MF) treatment, leading to new Janus kinase (JAK) inhibitors and other therapies for myeloproliferative neoplasms (MPNs). Research focuses on novel agents and combinations for improved clinical outcomes in MF and polycythemia vera.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Ruxolitinib's success in myelofibrosis (MF) highlights the importance of Janus kinase (JAK) inhibition in myeloproliferative neoplasms (MPNs).
- JAK/STAT signaling is a central mechanism in MPNs, driving the development of targeted therapies.
- Clinical improvement criteria now include symptom and spleen response in MF, influenced by ruxolitinib's efficacy.
Purpose of the Study:
- To review the current landscape of clinical drug development for MPNs.
- To highlight promising new agents and rational combination strategies.
- To discuss novel therapeutic approaches beyond JAK inhibition.
Main Methods:
- Review of clinical trial data and scientific literature on MPN therapeutics.
- Focus on agents targeting JAK/STAT pathways and other mechanisms.
- Analysis of combination therapies involving ruxolitinib and novel agents.
Main Results:
- Several JAK inhibitors are in development, aiming for improved safety profiles and efficacy.
- Ruxolitinib is approved for MF and polycythemia vera, with ongoing development for essential thrombocythemia.
- Novel agents with distinct mechanisms, including interferon formulations and antifibrotic therapies, are under investigation.
Conclusions:
- The development of targeted therapies and rational combinations is rapidly advancing MPN treatment.
- New agents offer potential for reduced myelosuppression and improved anemia management.
- Future strategies involve exploring diverse drug classes and combination regimens for optimal patient outcomes.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...